WUSTL

$32 million NIH grant funds study of multipurpose infection fighter

By Michael C. Purdy
Researcher
Robert Boston
Herbert W. Virgin IV, MD, PhD, is principal investigator for a new research collaborative that aims to develop drugs that can simultaneously fight multiple forms of infection. The project is funded by a new $32 million National Institutes of Health (NIH) grant.

A multi-institutional campaign to harness a newly recognized cellular defense against infection is being led by researchers at Washington University School of Medicine in St. Louis.

The project could lead to drugs with unprecedented versatility in fighting different infections. A $32 million grant from the National Institutes of Health (NIH) is funding the collaborative, which also includes Massachusetts General Hospital, the Broad Institute and the University of Texas Southwestern Medical Center. The grant creates a four-site Center for Excellence in Translational Research (CETR), which is a National Institutes of Allergy and Infectious Diseases program.

“If we’re successful, we may develop drugs that allow us to treat bacteria, viruses, fungi and parasites with a single medication,” said principal investigator Herbert W. Virgin IV, MD, PhD, head of Washington University's Department of Pathology and Immunology. “We now have drugs that can take on viruses or bacteria but nothing that can fight several types of infectious agents at the same time."

Virgin and his colleagues are investigating a newly recognized connection between a cellular waste disposal system called autophagy and the body’s ability to fend off infections.

Scientists already knew that autophagy proteins clean out cellular debris. But researchers recently have started to link the proteins to infection control, suggesting that the disposal system may not only take out the trash but also help identify unwanted cellular houseguests — such as bacteria, viruses, fungi or parasites — and destroy them. Other proteins involved in autophagy may fight infection in different ways, indicating that this pathway is a versatile tool used by the body to fight a range of infections.

“For example, several members of our CETR team from different institutions have reported evidence that some autophagy proteins are potent antiviral agents and that stimulating autophagy can control virus infection in animal models,” said Virgin, also the Edward Mallinckrodt Professor of Pathology and Immunology.

Other studies have suggested potential connections between autophagy and control of bacterial, parasitic and fungal infections.

The researchers will identify proteins involved in autophagy, explore the roles the proteins play in waste disposal and immunity, and attempt to develop drugs that engage the autophagy process in fighting infections.


Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

MEDIA CONTACTS
Michael C. Purdy
Senior Medical Sciences Writer
(314) 286-0122
purdym@wustl.edu